The nation of Zimbabwe has rejected a significant American health deal worth 367 million US dollars (£272m) over five years because of Washington's insistence on confidential biological samples.
This move was revealed following a official document from December was leaked, revealing that Head of State Emmerson Mnangagwa felt the deal was "lopsided".
A government representative has since clarified that the United States was demanding access to genetic material for scientific study and commercial purposes but refused to guarantee the benefits from any future medical innovations.
"We must now begin the difficult and regrettable task of scaling back our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had donated more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has urged more talks to reach a deal acceptable to all parties so the country's critical HIV treatment initiative can continue.
Broader Context
Zimbabwe's decision follows a comparable situation in neighbouring Kenya, where a court blocked a related health funding agreement following concerns were filed about the safety of Kenyans' medical information.
After returning to the presidency last year, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
USAID had managed aid for the US government, but Trump argued its expenditure was "wasteful" and his administration was seeking direct bilateral deals to boost openness and accountability.
As per statements, 16 African countries have so far agreed to similar agreements, representing more than $18.3bn in committed funds.
Specifics of the Declined Agreement
This assistance for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration might have yielded extraordinary advantages for Zimbabwean communities, especially the 1.2 million presently receiving antiretroviral therapy through American-funded initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to share its genetic material and health information for a long time, without any equivalent guarantee of access to any medical innovations – like vaccines, diagnostics, or treatments – that could result from that shared data," his statement read.
"In essence, our country would supply the raw materials for scientific discovery with no certainty that the resulting innovations would be accessible to our population if a new disease outbreak emerge."
Sovereignty and Global Health
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral health agreements were undermining frameworks already established via the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework created to manage potential global health emergencies.
"This framework is designed to guarantee that when a country contributes its samples, the benefits – such as vaccines and treatments – are distributed fairly, not monopolised exclusively by those with the capability to create them."
These objections over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We welcome ongoing dialogue with our American counterparts on how future collaboration might be designed in a way that honours the independence and dignity of each country."
Health Experts Reaction
A leading public health body said it understood the official position, but urged that talks need to persist given that a large portion of the nation's Aids initiatives relied on foreign aid.
"If technical issues arise, such as those involving information security or implementation frameworks, these can often be resolved through detailed discussion and mutually agreed protections," the group said.
The halted deal highlights the continuing debate between accepting vital international aid and protecting national sovereignty in an increasingly data-driven world.